Concepedia

Oral valganciclovir as preemptive therapy for cytomegalovirus infection post allogeneic stem cell transplantation

Alessandro Busca, Paolo de Fabritiis, Valeria Ghisetti, Tiziano Allice, M Mirabile, Giuseppe Gentile, Franco Locatelli, Michele Falda

Transplant Infectious Disease · 2007 · 62 citations · 11 references

DOI

Abstract

VGCV administered as preemptive therapy for CMV infection in patients receiving an allogeneic HSCT showed promise for treating this frequent complication. Prospective randomized studies in this setting are mandatory to yield more definitive results.

References

11

Efficacy and Safety of Valganciclovir vs. Oral Ganciclovir for Prevention of Cytomegalovirus Disease in Solid Organ Transplant Recipients

Carlos V. Payá, Atul Humar, Ed Dominguez et al. · American Journal of Transplantation · 2004 · 876 citations · Full text

Cytomegalovirus in Hematopoietic Stem Cell Transplant Recipients

Per Ljungman, Morgan Hakki, Michael Boeckh · Hematology/Oncology Clinics of North America · 2011 · 414 citations · Full text

, , +7

Valganciclovir Results in Improved Oral Absorption of Ganciclovir in Liver Transplant Recipients

Mark D. Pescovitz, John M. Rabkin, Robert M. Merion et al. · Antimicrobial Agents and Chemotherapy · 2000 · 360 citations · Full text

Oral Ganciclovir as Maintenance Treatment for Cytomegalovirus Retinitis in Patients with AIDS

William Drew, David Ives, Jacob Lalezari et al. · New England Journal of Medicine · 1995 · 287 citations · Full text

Pharmacokinetics of Valganciclovir and Ganciclovir Following Multiple Oral Dosages of Valganciclovir in HIV- and CMV-Seropositive Volunteers

Frances C. Brown, Ludger Banken, Kay L. Saywell et al. · Clinical Pharmacokinetics · 1999 · 153 citations

, , +8